Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1604- Cu,    Targeting copper metabolism: a promising strategy for cancer treatment
- Review, NA, NA
eff↓, eff↓, ROS↑, eff↑,
1603- Cu,  BP,  SDT,    Glutathione Depletion-Induced ROS/NO Generation for Cascade Breast Cancer Therapy and Enhanced Anti-Tumor Immune Response
- in-vitro, BC, 4T1 - in-vivo, NA, NA
GSH↓, Fenton↑, ROS↑, NO↑, sonoS↑, eff↑, NO↑, *toxicity∅, eff?,
1602- Cu,    A simultaneously GSH-depleted bimetallic Cu(ii) complex for enhanced chemodynamic cancer therapy†
- in-vitro, BC, MCF7 - in-vitro, BC, 4T1 - in-vitro, Lung, A549 - in-vitro, Liver, HepG2
eff↑, GSH↓, H2O2↑, ROS↑, *BioAv↑, selectivity↑, TumCCA↑, Apoptosis↑, Fenton↑, *toxicity?,
1600- Cu,    Cu(II) complex that synergistically potentiates cytotoxicity and an antitumor immune response by targeting cellular redox homeostasis
- Review, NA, NA
ER Stress↑, ROS↑, AntiTum↑, GSH↓, Ferroptosis↑, selectivity↑, GSH/GSSG↓, *ROS∅, eff↑,
1599- Cu,    Copper in tumors and the use of copper-based compounds in cancer treatment
- Review, NA, NA
ROS↑, RadioS↑,
1569- Cu,    Copper Nanoparticles as Therapeutic Anticancer Agents
- Review, NA, NA
Dose∅, Dose∅, ROS↑,
1570- Cu,    Development of copper nanoparticles and their prospective uses as antioxidants, antimicrobials, anticancer agents in the pharmaceutical sector
- Review, NA, NA
selectivity↑, antiOx↑, ROS↑, eff↑, GSH↓, lipid-P↑, Catalase↓, SOD↓, other↑,
1571- Cu,    Copper in cancer: From pathogenesis to therapy
- Review, NA, NA
*toxicity↝, ROS↑, lipid-P↓, HNE↑, MAPK↑, JNK↑, AP-1↑, Beclin-1/ATG6↑, ATG7↑, TumAuto↑, Apoptosis↑, HO-1↑, NQO1↑, mt-ROS↑, Fenton↑,
1572- Cu,    Recent Advances in Cancer Therapeutic Copper-Based Nanomaterials for Antitumor Therapy
- Review, NA, NA
eff↑, Fenton↑, ROS↑, eff↑, mtDam↑, BAX↑, Bcl-2↓, MMP↓, Cyt‑c↑, Casp3↑, ER Stress↑, CHOP/DDIT3↑, Apoptosis↑, selectivity↑, eff↑, Pyro↑, Paraptosis↑, Cupro↑, ChemoSen↑, eff↑,
1595- Cu,    The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy
- Review, NA, NA
eff↑, ROS↑, eff↓,
1598- Cu,    Targeting copper in cancer therapy: 'Copper That Cancer'
- Review, NA, NA
eff↓, eff↑, Dose∅, eff↑, angioG↑, ROS↑,
1597- Cu,    Anticancer potency of copper(II) complexes of thiosemicarbazones
- Review, NA, NA
eff↑, ROS↑,
1596- Cu,  CDT,    Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review
- Review, NA, NA
TumCD↑, Apoptosis↓, ROS↑, angioG↑, Cupro↑, Paraptosis↑, eff↑, eff↓, selectivity↑, DNAdam↑, eff↑, eff↑, eff↑, eff↑, Fenton↑, H2O2↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, eff↑, *toxicity↝, other↑, eff↑,
6176- Cu,    Copper Oxide Nanoparticles Induced Mitochondria Mediated Apoptosis in Human Hepatocarcinoma Cells
- in-vitro, Liver, HepG2
ROS↑, P53↑, MMP↓, Bax:Bcl2↑, Apoptosis↑, *Bacteria↓, MDA↑, GSH↓, eff↓, Casp3↑,
6177- Cu,    Toxicity of copper oxide nanoparticles: a review study
- Review, Nor, NA
*ROS↑, *Inflam↑, *toxicity↑, lipid-P↑, GSH↓, MDA↑, *SOD↓, *Catalase↓,
6171- Cu,    Copper in the tumor microenvironment and tumor metastasis
- Review, Var, NA
*angioG↑, other↑, *ROS↑, CTR1↝, other↝, COX17↝, ATOX1↝,
6170- Cu,    Copper induces cell death by targeting lipoylated TCA cycle proteins
- in-vitro, Var, NA
TCA↓, toxicity↝, Cupro↑,
6182- Cu,    Role of cuproptosis in digestive system tumors (Review)
- Review, Var, NA
Cupro↑, TumCG↓, Apoptosis↑, ROS↑, Ferroptosis↑, ETC↓, MMP↓, Ca+2↑, Fenton↑, lipid-P↑, MPT↑, ATP↓, Cyt‑c↑, Casp↑, angioG↑, TumCP↑, TumCMig↑, TumCI↑, TumMeta↑, DDS↑, eff↑,
6183- Cu,    Copper(II) oxide nanoparticles penetrate into HepG2 cells, exert cytotoxicity via oxidative stress and induce pro-inflammatory response
- in-vitro, Liver, HepG2
ROS↑, MAPK↑, ERK↑, AP-1↑,
6187- Cuc,    Cucurbitacin I inhibits STAT3, but enhances STAT1 signaling in human cancer cells in vitro through disrupting actin filaments
- in-vitro, Lung, A549
STAT3↓,
6196- Cuc,    Cucurbitacins – A Promising Target for Cancer Therapy
- Review, Var, NA
STAT3↓, toxicity↝, COX2/PTGS2↓, TumCG↓, TumCCA↑, Apoptosis↑, STAT3↓, JAK2↓,
6186- Cuc,    Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity
- vitro+vivo, Lung, A549 - in-vitro, BC, MDA-MB-453
STAT3↓, JAK2↓, TumCG↓,
6188- Cuc,    Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
TumCCA↑, p‑H3↓, cl‑PARP↑, Casp↑, AntiCan↑, JAK2↓, STAT3↓,
6189- Cuc,    Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells
- in-vitro, Lung, A549
TumCP↓, Apoptosis↑, TumCCA↑, CycB/CCNB1↓, Cyt‑c↑, STAT3↓, Casp3↑, Casp9↑, MMP↓,
6190- Cuc,    Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells
- in-vitro, Colon, SW480
ROS↑, TumCCA↑, Apoptosis↑, CycB/CCNB1↓, CDC25↓, Casp↓, eff↓,
6191- Cuc,    Growth inhibitory effect of Cucurbitacin E on breast cancer cells
- in-vitro, BC, MDA-MB-231
TumCG↓, TumCCA↑, Apoptosis↑, Casp3↑, P21↑, p27/CDKN1B↑, ChemoSen↑, STAT3↓,
6192- Cuc,    Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway
- vitro+vivo, CRC, NA
TumCP↓, TumCCA↑, CD44↓, CSCs↓, NOTCH↓,
6193- Cuc,    Cucurbitacin E Inhibits Huh7 Hepatoma Carcinoma Cell Proliferation and Metastasis via Suppressing MAPKs and JAK/STAT3 Pathways
- in-vitro, Liver, HUH7
TumCP↓, TumCMig↓, JAK↓, STAT3↓,
6194- Cuc,    Pharmacokinetics of cucurbitacin B from Trichosanthes cucumerina L. in rats
- in-vivo, Nor, NA
*BioAv↓, *Half-Life↝, *AST∅, *ALAT∅, *RenoP↝, *Half-Life↝,
6195- Cuc,    Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends
- Review, Var, NA
TumCG↓, Apoptosis↑, TumCCA↑, TumMeta↓, angioG↓, chemoPv↑, BioAv↓, Half-Life↝, cycD1/CCND1↓, cycE/CCNE↓, Casp3↑, cl‑PARP↑, JNK↑, Akt↓, ERK↓, survivin↓, XIAP↓, Bcl-2↓, Mcl-1↓, ROS↑, NRF2↓, FAK↓, MMP9↓, VEGF↓, VEGFR2/KDR/Flk1↓, *NF-kB↓, TLR4↝, NLRP3↑, Pyro↑, GSH↓,
6185- Cuc,    Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics
- Review, Var, NA - Review, Arthritis, NA - Review, AD, NA
*Inflam↓, *antiOx↑, *hepatoP↑, *neuroP↑, *AntiCan↑, *toxicity↝, *BioAv↓, *HO-1↑, *NRF2↑, *NLRP3↑, *SOD↑, *SOD1↑, *ROS↓, *AntiAge↑, *ARE↑, *STAT↓, *NF-kB↓, *neuroG↑, *memory↑, ROS↑, NLRP3↑, CIP2A↓, Akt↓, STAT3↑, VEGFR2/KDR/Flk1↓, DNMTs↓, MAPK↓, YAP/TEAD↓, PI3K↓, Wnt↓, NOTCH↓, TumCCA↑, TumCG↓, TumCP↓, FAK↑, MMP9↓, TumAuto↑, toxicity↝, BioAv↓, Half-Life↝, BioAv↑, selectivity∅,
6184- Cuc,    Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells
- vitro+vivo, PC, NA
TumCG↓, TumCCA↑, Apoptosis↑, JAK2↓, STAT3↓, STAT5↓, P21↑, cycA1/CCNA1↓, CycB/CCNB1↓, Bcl-xL↓, ChemoSen↑, TumVol↓, toxicity↓,
6197- Cuc,    Cucurbitacin B inhibits growth and induces apoptosis through the JAK2/STAT3 and MAPK pathways in SH‑SY5Y human neuroblastoma cells
- in-vitro, neuroblastoma, SH-SY5Y
TumCCA↑, Apoptosis↑, p‑JAK3↓, p‑STAT3↓, P53↑, P21↑,
6198- Cuc,    Comparison of the pharmacokinetic profiles of three triterpenoids after oral administration of a cucurbitacin tablet and nanosuspension by UHPLC-MS/MS
- in-vivo, Nor, NA
*BioAv↑, *Half-Life↑,
6199- Cuc,    Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells
- in-vitro, BC, MCF7
TumCCA↑, survivin↓,
6200- Cuc,  GEM,    Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer
- in-vivo, PC, NA
eff↑, TumCG↓, Bcl-xL↓, Bcl-2↓, cMyc↓, Casp↑, STAT3↓, JAK2↓,
6201- Cuc,    Cucurbitacin B and Its Derivatives: A Review of Progress in Biological Activities
- Review, Var, NA - Review, AD, NA
*toxicity↑, *antiOx↑, *Inflam↓, *NLRP3↓, *NF-kB↓, *neuroP↑, *memory↑, *GABA↑, *cardioP↑, AntiTum↑, p‑FAK↓, ROS↑, TumMeta↑, TumCP↓, Apoptosis↑, P53↑, P21↑, TumCCA↑, p27/CDKN1B↑, CDK4↓, CDK2↓, cycD1/CCND1↓, cycE/CCNE↓, STAT3↓, ChemoSen↑, MMP2↓, MMP9↓, VEGF↓, TumCMig↓, angioG↓, NOTCH↓, EMT↓, toxicity↑, BioAv↑, EPR↑,
6202- Cuc,    Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms
- Review, Var, NA
*Inflam↓, *antiOx↑, *hepatoP↑, AntiTum↑, AntiCan↑, *chemoPv↑, *AntiDiabetic↑, *Imm↑, Hif1a↓, P-gp/ABCB1↓, mTORC1↓, ERK↓, Akt↓, Casp3↑, Casp7↑, ATP↓, RadioS↑, ChemoSen↑,
6203- Cuc,  immuno,    Isocucurbitacin B targets STAT3 to induce ferroptosis and promote anti-PD1 immunotherapy responses in breast cancer
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, BC, 4T1
Ferroptosis↑, STAT3↓, GPx4↓, Imm↑, PD-L1↓, TumCG↓, ATP↓, OXPHOS↓,
6204- Cuc,    Preliminary investigation of the anti-colon cancer activity of cucurbitacin C from cucumber: A network pharmacological study and experimental validation
- in-vitro, Colon, HCT116
TumCP↓, TumCMig↓, TumCG↓, MMP1↓, MMP3↓, MMP9↓, MMP13↓, Apoptosis↑,
1590- Cuc,    ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism
- Review, NA, NA
ACLY↓,
1609- CUR,  EA,    Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells
- in-vitro, Cerv, NA
eff↑, Dose∅, ROS↑, DNAdam↑, P53↑, P21↑, BAX↑, Dose∅,
1616- CUR,  EA,    Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid
- in-vitro, Nor, NA
*MAOA↓, *Dose∅, Dose?,
1982- CUR,    Inhibition of thioredoxin reductase by curcumin analogs
- in-vitro, NA, NA
eff↑, TrxR↓,
1981- CUR,    Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity
- in-vitro, Lung, NA
eff↑, ROS↑, mt-GSH↓, Bax:Bcl2↑, Cyt‑c↑, MMP↓, Casp3↑, Trx2↓, TrxR↓, mt-DNAdam↑,
1980- CUR,  Rad,    Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells
- in-vitro, Cerv, HeLa - in-vitro, Laryn, FaDu
selectivity↑, RadioS↑, TrxR↓, ROS↑, ERK↑, Dose∅, cl‑PARP↑,
1979- CUR,  Rad,    Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase
- in-vitro, Lung, A549
eff↑, ROS↑, GSH/GSSG↓, TrxR↓, selectivity↑,
1978- CUR,    Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells
- in-vitro, Cerv, HeLa
TrxR1↓, ROS↑, DNA-PK↑, eff↑, Trx↓, Trx1↓,
1977- CUR,    Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors
- in-vitro, BC, MCF7 - in-vitro, Cerv, HeLa - in-vitro, Lung, A549
TrxR↓, Dose↝, eff↑,
1792- CUR,  LEC,    Chondroprotective effect of curcumin and lecithin complex in human chondrocytes stimulated by IL-1β via an anti-inflammatory mechanism
- in-vitro, Arthritis, RAW264.7 - NA, NA, HCC-38
*Inflam↓, *NF-kB↓, *iNOS↓, *COX2/PTGS2↓, *NO↓, *PGE2↓, *MMPs↑, *TIMP1↑, *BioEnh↑,

Showing Research Papers: 2601 to 2650 of 8269
Prev Page 53 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↓, 1,   Fenton↑, 6,   Ferroptosis↑, 3,   GPx4↓, 1,   GSH↓, 7,   mt-GSH↓, 1,   GSH/GSSG↓, 2,   H2O2↑, 2,   HNE↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   lipid-P↑, 3,   MDA↑, 2,   NQO1↑, 1,   NRF2↓, 1,   OXPHOS↓, 1,   ROS↑, 25,   mt-ROS↑, 1,   SOD↓, 1,   Trx↓, 1,   Trx1↓, 1,   Trx2↓, 1,   TrxR↓, 5,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 3,   CDC25↓, 1,   COX17↝, 1,   ETC↓, 1,   MMP↓, 5,   MPT↑, 1,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 1,   ATG7↑, 1,   cMyc↓, 1,   TCA↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   Apoptosis↓, 1,   Apoptosis↑, 14,   BAX↑, 2,   Bax:Bcl2↑, 2,   Bcl-2↓, 3,   Bcl-xL↓, 2,   Casp↓, 1,   Casp↑, 3,   Casp3↑, 7,   Casp7↑, 1,   Casp9↑, 1,   Cupro↑, 4,   Cyt‑c↑, 4,   Ferroptosis↑, 3,   JNK↑, 2,   MAPK↓, 1,   MAPK↑, 2,   Mcl-1↓, 1,   p27/CDKN1B↑, 2,   Paraptosis↑, 2,   Pyro↑, 2,   survivin↓, 2,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑H3↓, 1,   other↑, 3,   other↝, 1,   sonoS↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNA-PK↑, 1,   DNAdam↑, 2,   mt-DNAdam↑, 1,   DNMTs↓, 1,   P53↑, 4,   cl‑PARP↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 2,   P21↑, 5,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   CIP2A↓, 1,   CSCs↓, 1,   EMT↓, 1,   ERK↓, 2,   ERK↑, 2,   mTORC1↓, 1,   NOTCH↓, 3,   PI3K↓, 1,   STAT3↓, 12,   STAT3↑, 1,   p‑STAT3↓, 1,   STAT5↓, 1,   TumCG↓, 10,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AP-1↑, 2,   ATOX1↝, 1,   Ca+2↑, 1,   FAK↓, 1,   FAK↑, 1,   p‑FAK↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 4,   TumCI↑, 1,   TumCMig↓, 3,   TumCMig↑, 1,   TumCP↓, 6,   TumCP↑, 1,   TumMeta↓, 1,   TumMeta↑, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   angioG↑, 3,   EPR↑, 1,   Hif1a↓, 1,   NO↑, 2,   VEGF↓, 2,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

CTR1↝, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   Imm↑, 1,   JAK↓, 1,   JAK2↓, 5,   p‑JAK3↓, 1,   PD-L1↓, 1,   TLR4↝, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   ChemoSen↑, 6,   DDS↑, 1,   Dose?, 1,   Dose↝, 1,   Dose∅, 6,   eff?, 1,   eff↓, 7,   eff↑, 31,   Half-Life↝, 2,   RadioS↑, 4,   selectivity↑, 7,   selectivity∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 3,   chemoPv↑, 1,   toxicity↓, 1,   toxicity↑, 1,   toxicity↝, 3,   TumVol↓, 1,  
Total Targets: 156

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   ARE↑, 1,   Catalase↓, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 2,   ROS∅, 1,   SOD↓, 1,   SOD↑, 1,   SOD1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT∅, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

neuroG↑, 1,   STAT↓, 1,  

Migration(tgid=13) ⓘ

MMPs↑, 1,   TIMP1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,   NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   Imm↑, 1,   Inflam↓, 4,   Inflam↑, 1,   NF-kB↓, 4,   PGE2↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

GABA↑, 1,   MAOA↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,   NLRP3↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioEnh↑, 1,   Dose∅, 1,   Half-Life↑, 1,   Half-Life↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT∅, 1,   AST∅, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 1,   chemoPv↑, 1,   hepatoP↑, 2,   memory↑, 2,   neuroP↑, 2,   RenoP↝, 1,   toxicity?, 1,   toxicity↑, 2,   toxicity↝, 3,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 51

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page